|Bid||110.00 x 1000|
|Ask||143.00 x 1400|
|Day's Range||138.15 - 140.37|
|52 Week Range||42.62 - 148.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today that it has acquired TypeZero Technologies, Inc. (“TypeZero”). TypeZero’s offering includes the inControl diabetes management system, designed to provide personalized diabetes management solutions including technology to automatically adjust and regulate insulin delivery. Dexcom, TypeZero and the University of Virginia have had a longstanding, productive relationship in developing important technologies for diabetes management, including inControl for integration with both automated insulin delivery (“AID”) and smart pens.
NEW YORK, NY / ACCESSWIRE / August 3, 2018 / DexCom and Exact Sciences Corporation went in separate directions after reporting second quarter results. DexCom exploded and hit a new high after reporting an earnings beat while Exact Sciences slipped almost 13% after missing its revenue expectations. DexCom, Inc. shares closed up 30.65% on nearly 7 million shares traded.
DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today that Terry Gregg has retired as the Company’s Executive Chairman and from the Company’s Board of Directors after 13 years with Dexcom. Kevin Sayer has been appointed Chairman of the Board, in addition to his current duties as President and CEO.
Stock Research Monitor: CGIX, CHEK, and EXAS LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on DXCM sign up now at www.wallstequities.com/registration . Today's research on WallStEquities.com ...
DexCom, Inc. today announced that it plans to release its second quarter 2018 financial results after market close on Wednesday, August 1, 2018. Management will hold a conference call to review the company's second quarter 2018 performance starting at 4:30 p.m.
Dexcom, Inc. (DXCM), a leader in continuous glucose monitoring (CGM), announced today that the company has received CE Mark for its Dexcom G6 System for people with diabetes ages two years and up. “The Dexcom G6 represents the future of diabetes management. Not only does the product eliminate the need for fingersticks, but it also maintains the performance, connectivity and accuracy that the diabetes community has come to expect from Dexcom CGM,” said John Lister, Dexcom’s General Manager for EMEA.
Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today the U.S. Centers for Medicare & Medicaid Services (CMS) is updating its policy on mobile device compatibility for the Dexcom G5® CGM System. Available on iOS and Android, the Dexcom G5 is the first and only mobile-enabled CGM system for Medicare patients with diabetes that works to display and share real-time glucose activity. Medicare’s published coverage policy for CGMs will be modified to support the use of CGMs in conjunction with a smartphone, including the important data sharing function they provide for patients and their families.
SALEM, N.H. and WILSONVILLE, Ore., June 5, 2018 /PRNewswire/ -- AgaMatrix, Inc., a developer of diagnostic technologies for glucose monitoring and wholly owned subsidiary of AgaMatrix Holdings LLC, announced a prevailing outcome in a retaliatory patent infringement lawsuit brought by Dexcom, Inc. (NASDAQ: DXCM). In a decision ruled earlier this year by the US District Court for the Central District of California, the honorable Judge S. James Otero granted summary judgment of non-infringement in favor of AgaMatrix, citing that AgaMatrix did not infringe upon Dexcom's U.S. Patent No 7,081,195.
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Laboratories & Research stocks: DexCom Inc. (NASDAQ: DXCM), Exact Sciences Corp. (NASDAQ: EXAS), iKang Healthcare Group Inc. (NASDAQ: KANG), and Invitae Corp. (NYSE: NVTA).
Stock Monitor: Cancer Genetics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 10, 2018 / Active-Investors.com has just released a free earnings report on DexCom, Inc. (NASDAQ: DXCM ). If you want ...
DexCom, Inc. today announced that it plans to release its first quarter 2018 financial results after market close on Wednesday, May 2, 2018. Management will hold a conference call to review the company's first quarter 2018 performance starting at 4:30 p.m.
DexCom, Inc. , the leader in continuous glucose monitoring is pleased to announce that the U.S. Food and Drug Administration has granted a De Novo request for the Dexcom G6® CGM System, the newest generation of CGM for people with diabetes ages 2 and up.
NEW YORK, NY / ACCESSWIRE / March 26, 2018 / Rising concerns over a potential trade war with China continued to drag markets down on Friday, with the Dow Jones plummeting more than 400 points. The Dow ...
The US Patent Office Patent Trial and Appeal Board recently ruled to uphold the validity of WaveForm Technologies Inc. patents in the emerging field of continuous glucose monitoring SALEM, N.H. and WILSONVILLE, ...
DexCom, Inc. today reported its financial results as of and for the quarter and fiscal year ended December 31, 2017.
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / DexCom, Inc. (NASDAQ: DXCM ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 4:30 PM Eastern Time. ...
DexCom, Inc. (DXCM), has today released the findings of the HypoDE study, a multi-centre, randomised controlled trial (RCT) which was discussed on Friday 15th February at ATTD. The study found that the use of Dexcom continuous glucose monitoring (CGM) reduces the frequency and severity of hypoglycaemic events among high-risk individuals with type 1 diabetes treated with multiple daily injections (MDI) of insulin. Hypoglycaemia remains a key limiting factor in achieving optimal glycaemic control in people with type 1 diabetes, and the vast majority of these individuals are treated with MDI globally.
DexCom, Inc. today announced that management will present an update on DexCom at the following upcoming investor conferences: